Logo image of MOLN

MOLECULAR PARTNERS AG -ADR (MOLN) Stock Fundamental Analysis

NASDAQ:MOLN - Nasdaq - US60853G1067 - ADR - Currency: USD

3.665  +0.19 (+5.32%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MOLN. MOLN was compared to 551 industry peers in the Biotechnology industry. The financial health of MOLN is average, but there are quite some concerns on its profitability. MOLN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MOLN had negative earnings in the past year.
In the past year MOLN has reported a negative cash flow from operations.
MOLN had negative earnings in 4 of the past 5 years.
MOLN had negative operating cash flow in 4 of the past 5 years.
MOLN Yearly Net Income VS EBIT VS OCF VS FCFMOLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

MOLN has a Return On Assets of -34.09%. This is in the better half of the industry: MOLN outperforms 61.89% of its industry peers.
MOLN has a Return On Equity of -38.16%. This is in the better half of the industry: MOLN outperforms 71.51% of its industry peers.
Industry RankSector Rank
ROA -34.09%
ROE -38.16%
ROIC N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
MOLN Yearly ROA, ROE, ROICMOLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

Looking at the Gross Margin, with a value of 99.80%, MOLN belongs to the top of the industry, outperforming 99.27% of the companies in the same industry.
MOLN's Gross Margin has been stable in the last couple of years.
MOLN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
MOLN Yearly Profit, Operating, Gross MarginsMOLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

MOLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MOLN has been increased compared to 1 year ago.
The number of shares outstanding for MOLN has been increased compared to 5 years ago.
Compared to 1 year ago, MOLN has an improved debt to assets ratio.
MOLN Yearly Shares OutstandingMOLN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
MOLN Yearly Total Debt VS Total AssetsMOLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

MOLN has an Altman-Z score of 1.55. This is a bad value and indicates that MOLN is not financially healthy and even has some risk of bankruptcy.
MOLN has a better Altman-Z score (1.55) than 68.78% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that MOLN is not too dependend on debt financing.
The Debt to Equity ratio of MOLN (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.55
ROIC/WACCN/A
WACC4.95%
MOLN Yearly LT Debt VS Equity VS FCFMOLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

MOLN has a Current Ratio of 14.31. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
MOLN has a better Current ratio (14.31) than 86.75% of its industry peers.
MOLN has a Quick Ratio of 14.31. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
MOLN has a better Quick ratio (14.31) than 86.93% of its industry peers.
Industry RankSector Rank
Current Ratio 14.31
Quick Ratio 14.31
MOLN Yearly Current Assets VS Current LiabilitesMOLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.75% over the past year.
Looking at the last year, MOLN shows a very negative growth in Revenue. The Revenue has decreased by -60.65% in the last year.
Measured over the past years, MOLN shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)40.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.96%
Revenue 1Y (TTM)-60.65%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, MOLN will show a decrease in Earnings Per Share. The EPS will decrease by -2.09% on average per year.
MOLN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 93.72% yearly.
EPS Next Y7.01%
EPS Next 2Y5.2%
EPS Next 3Y15.32%
EPS Next 5Y-2.09%
Revenue Next Year-75%
Revenue Next 2Y65.83%
Revenue Next 3Y128.15%
Revenue Next 5Y93.72%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MOLN Yearly Revenue VS EstimatesMOLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
MOLN Yearly EPS VS EstimatesMOLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MOLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MOLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MOLN Price Earnings VS Forward Price EarningsMOLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MOLN Per share dataMOLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

MOLN's earnings are expected to grow with 15.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.2%
EPS Next 3Y15.32%

More info and screens

0

5. Dividend

5.1 Amount

MOLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULAR PARTNERS AG -ADR

NASDAQ:MOLN (8/7/2025, 8:00:01 PM)

3.665

+0.19 (+5.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)08-25 2025-08-25
Inst Owners45.02%
Inst Owner Change0%
Ins Owners4%
Ins Owner ChangeN/A
Market Cap135.15M
Analysts82.22
Price Target13.14 (258.53%)
Short Float %0.11%
Short Ratio14.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.44%
PT rev (3m)4.06%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.97
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS0.17
BVpS4.75
TBVpS4.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.09%
ROE -38.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.52%
Cap/Sales 14.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.31
Quick Ratio 14.31
Altman-Z 1.55
F-Score4
WACC4.95%
ROIC/WACCN/A
Cap/Depr(3y)41.08%
Cap/Depr(5y)46.5%
Cap/Sales(3y)8.93%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.96%
EPS Next Y7.01%
EPS Next 2Y5.2%
EPS Next 3Y15.32%
EPS Next 5Y-2.09%
Revenue 1Y (TTM)-60.65%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year-75%
Revenue Next 2Y65.83%
Revenue Next 3Y128.15%
Revenue Next 5Y93.72%
EBIT growth 1Y31.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.56%
EBIT Next 3Y20.63%
EBIT Next 5YN/A
FCF growth 1Y-0.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.41%
OCF growth 3YN/A
OCF growth 5YN/A